

Katherine B Chiappinelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2032053/publications.pdf>

Version: 2024-02-01

19
papers

4,170
citations

623574

14
h-index

752573

20
g-index

21
all docs

21
docs citations

21
times ranked

7754
citing authors

#	ARTICLE	IF	CITATIONS
1	Transposable element regulation and expression in cancer. <i>FEBS Journal</i> , 2022, 289, 1160-1179.	2.2	60
2	Inhibiting DNA methylation improves antitumor immunity in ovarian cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	7
3	The HIV Latency Reversal Agent HODHBt Enhances NK Cell Effector and Memory-Like Functions by Increasing Interleukin-15-Mediated STAT Activation. <i>Journal of Virology</i> , 2022, 96, .	1.5	5
4	Locus-Specific Characterization of Human Endogenous Retrovirus Expression in Prostate, Breast, and Colon Cancers. <i>Cancer Research</i> , 2021, 81, 3449-3460.	0.4	20
5	Epigenetic Therapies in Ovarian Cancer Alter Repetitive Element Expression in a <i>TP53</i> -Dependent Manner. <i>Cancer Research</i> , 2021, 81, 5176-5189.	0.4	15
6	Editorial: Genetic and Epigenetic Control of Immune Responses. <i>Frontiers in Immunology</i> , 2021, 12, 775101.	2.2	2
7	Combining epigenetic and immune therapy to overcome cancer resistance. <i>Seminars in Cancer Biology</i> , 2020, 65, 99-113.	4.3	92
8	Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer. <i>Scientific Reports</i> , 2020, 10, 3470.	1.6	72
9	The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. <i>Cancer Immunology Research</i> , 2019, 7, 923-938.	1.6	148
10	Epigenetic therapy for ovarian cancer: promise and progress. <i>Clinical Epigenetics</i> , 2019, 11, 7.	1.8	181
11	Reply to Haffner et al.: DNA hypomethylation renders tumors more immunogenic. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8583-E8584.	3.3	5
12	Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E10981-E10990.	3.3	217
13	Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. <i>Cell</i> , 2017, 171, 1284-1300.e21.	13.5	366
14	Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells. <i>PLoS ONE</i> , 2017, 12, e0179501.	1.1	79
15	Unraveling the molecular pathways of DNA-methylation inhibitors: human endogenous retroviruses induce the innate immune response in tumors. <i>Oncotmunology</i> , 2016, 5, e1122160.	2.1	34
16	Combining Epigenetic and Immunotherapy to Combat Cancer. <i>Cancer Research</i> , 2016, 76, 1683-1689.	0.4	251
17	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 668-679.	12.8	839
18	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. <i>Cell</i> , 2015, 162, 974-986.	13.5	1,408

#	ARTICLE	IF	CITATIONS
19	Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. <i>Oncotarget</i> , 2014, 5, 587-598.	0.8	367